Showing 1961 - 1970 of 2142 for "Tian Yuan Law Firm" with applied filters
09 August 2017 by
Asialaw Leading Lawyers 2017 is now live on this website.
08 August 2017 by
Latest moves and updates from Hong Kong, India and Singapore
07 August 2017 by
Japan has launched significant new corporate governance reform by revising its Stewardship Code, which requires institutional investors to disclose voting records for investments and establish governance structures to prevent conflicts of interest. The challenges will be in how the changes are implemented ahead, including how existing legislation might conflict with the controversial subject of collective engagement between investors and the companies they invest in.
03 August 2017 by
Latest partner moves from India, Australia and Singapore
02 August 2017 by
From the Taj Mahal Palace Hotel to the Nokia ringtone and the stripes of 7-Eleven convenience stores, Karry Lai explains why non-traditional trade mark innovation in Asia is more than meets the eye
01 August 2017 by
Laos amends investment law to attract business in targeted sectors
31 July 2017 by
Jaclyn Jhin, managing director and chief legal and compliance officer, CLSA, tells Asialaw about what it takes to be a successful in-house counsel, and the value of mentoring.
28 July 2017 by
Policymakers, academics and lawyers at a conference in Hong Kong last month spoke of the “immense opportunities” for investors in Asia in sectors such as transport and energy generation under the One Belt One Road (OBOR) initiative. They warned, however, that investors in the 65 countries along the route of OBOR must be aware of the risks in putting their money into emerging economies that may not be equipped with robust legal frameworks.
27 July 2017 by
The China Food and Drug Administration (CFDA) is planning to introduce a patent linkage scheme that will require a generic applicant to make a non-infringement declaration against an innovator’s patent portfolio. By creating this linkage, innovators can rest assured that their innovations are protected while generic drug companies are motivated to get regulatory approval for entry into market by proving that a patent is invalid or not infringed. However, observers warn of potential challenges in implementation.
26 July 2017 by
Latest partner moves from Singapore, Indonesia and more
